Back to GetFilings.com
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED: SEPTEMBER 30, 2004
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM: _______ TO _________
COMMISSION FILE NO.: 0-19974
ICU MEDICAL, INC.
(EXACT NAME OF REGISTRANT AS PROVIDED IN CHARTER)
------------------------------------------------
DELAWARE 33-0022692
-------- ----------
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
951 CALLE AMANECER, SAN CLEMENTE, CALIFORNIA 92673
- -------------------------------------------- -----
(Address of Principal Executive Offices) (Zip Code)
(949) 366-2183
--------------
(Registrant's Telephone No. Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days:
Yes [XXX] No [ ]
Indicate the number of shares outstanding in each of the issuer's classes of
common stock, as of the latest practicable date:
CLASS OUTSTANDING AT OCTOBER 31, 2004
----- -------------------------------
Common 13,570,469
ICU MEDICAL, INC.
INDEX
PART I - FINANCIAL INFORMATION PAGE NUMBER
- ------------------------------ -----------
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
- ------- --------------------------------
Condensed Consolidated Balance Sheets, September 30, 2004 and
December 31, 2003 3
Condensed Consolidated Statements of Income (Loss) for the three
and nine months ended September 30, 2004 and 2003 4
Condensed Consolidated Statements of Cash Flows for the nine months
ended September 30, 2004 and 2003 5
Condensed Consolidated Statements of Comprehensive Income (Loss) for
the nine months ended September 30, 2004 and 2003 6
Notes to Condensed Consolidated Financial Statements 7
ITEM 2.
- -------
Management's Discussion and Analysis of Financial Condition
and Results of Operations 10
ITEM 3.
- -------
Quantitative and Qualitative Disclosures About Market Risk 25
ITEM 4.
- -------
Controls and Procedures 25
PART II - OTHER INFORMATION 26
- ---------------------------
SIGNATURES 28
2
ICU MEDICAL, INC.
Condensed Consolidated Balance Sheets
September 30, 2004 and December 31, 2003
(all dollar amounts in thousands except per share data)
(unaudited)
ASSETS
9/30/04 12/31/03
---------- ----------
CURRENT ASSETS:
Cash and cash equivalents $ 6,154 $ 1,787
Liquid investments 75,425 71,350
---------- ----------
Cash, cash equivalents and liquid investments 81,579 73,137
---------- ----------
Accounts receivable, net of allowance for doubtful accounts of $627
and $742 as of September 30, 2004 and December 31, 2003, respectively 14,437 24,943
Finance loans receivable - current portion 2,799 4,142
Inventories 9,557 3,398
Prepaid income taxes 3,425 1,662
Prepaid expenses and other current assets 1,931 1,927
Deferred income taxes - current portion 2,006 2,008
---------- ----------
Total current assets 115,734 111,217
---------- ----------
PROPERTY AND EQUIPMENT, at cost: 73,561 71,615
Less--Accumulated depreciation (32,484) (30,574)
---------- ----------
41,077 41,041
---------- ----------
FINANCE LOANS RECEIVABLE - non-current portion 3,841 4,765
DEFERRED INCOME TAXES - non-current portion 2,054 2,680
INTANGIBLE ASSETS - net 3,934 4,166
OTHER ASSETS 432 419
---------- ----------
$ 167,072 $ 164,288
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 2,187 $ 3,051
Accrued liabilities 6,431 5,234
---------- ----------
Total current liabilities 8,618 8,285
---------- ----------
MINORITY INTEREST 1,051 --
STOCKHOLDERS' EQUITY:
Convertible preferred stock, $1.00 par value
Authorized -- 500,000 shares, issued and outstanding -- none -- --
Common stock, $0.10 par value-
Authorized -- 80,000,000 shares, issued -- 14,158,612 shares 1,416 1,416
Additional paid-in capital 61,775 63,535
Treasury stock, at cost -- 588,143 and 471,390 shares at
September 30, 2004 and December 31, 2003, respectively (15,418) (12,116)
Retained earnings 109,505 102,991
Accumulated other comprehensive income 125 177
---------- ----------
Total stockholders' equity 157,403 156,003
---------- ----------
$ 167,072 $ 164,288
========== ==========
The accompanying notes are an integral part of
these condensed consolidated financial statements.
3
Condensed Consolidated Statements of Income (Loss)
For the Three Months and Nine Months Ended
September 30, 2004 and Sepember 30, 2003
(all dollar amounts in thousands except per share data)
(unaudited)
For the Three Months Ended For the Nine Months Ended
-------------------------------- --------------------------------
9/30/04 9/30/03 9/30/04 9/30/03
------------- ------------- ------------- -------------
REVENUES:
Net sales $ 15,894 $ 25,016 $ 58,166 $ 73,616
Other 574 508 2,200 3,967
------------- ------------- ------------- -------------
TOTAL REVENUE 16,468 25,524 60,366 77,583
------------- ------------- ------------- -------------
COST OF GOODS SOLD 9,954 13,246 29,368 35,418
------------- ------------- ------------- -------------
Gross profit 6,514 12,278 30,998 42,165
------------- ------------- ------------- -------------
OPERATING EXPENSES:
Selling, general and administrative 6,807 5,387 19,065 17,017
Research and development 1,763 419 2,617 1,427
------------- ------------- ------------- -------------
Total operating expenses 8,570 5,806 21,682 18,444
------------- ------------- ------------- -------------
Income (loss) from operations (2,056) 6,472 9,316 23,721
INVESTMENT INCOME 375 313 1,083 883
------------- ------------- ------------- -------------
Income (loss) before income taxes
and minority interest (1,681) 6,785 10,399 24,604
PROVISION (BENEFIT) FOR INCOME TAXES (621) 2,610 3,909 9,460
MINORITY INTEREST (24) -- (24) --
------------- ------------- ------------- -------------
NET INCOME (LOSS) $ (1,036) $ 4,175 $ 6,514 $ 15,144
============= ============= ============= =============
NET INCOME (LOSS) PER SHARE
Basic ($ 0.08) $ 0.31 $ 0.47 $ 1.10
Diluted ($ 0.08) $ 0.28 $ 0.43 $ 1.00
WEIGHTED AVERAGE NUMBER OF SHARES
Basic 13,685,053 13,603,733 13,731,015 13,790,843
Diluted 13,685,053 14,805,056 14,996,073 15,073,761
The accompanying notes are an integral part of
these condensed consolidated financial statements.
4
ICU MEDICAL, INC.
Condensed Consolidated Statements of Cash Flows
For the Nine Months Ended
September 30, 2004 and September 30, 2003
(all dollar amounts in thousands)
(unaudited)
For the Nine Months Ended
-------------------------
9/30/04 9/30/03
--------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income $ 6,514 $ 15,144
Adjustments to reconcile net income to net cash
provided by operating activities --
Depreciation and amortization 5,564 5,105
Write-off of in-process research and development 1,154 --
Net change in accounts receivable 10,506 805
Net change in inventory (6,159) 1,883
Net change in income tax accounts (1,135) (4,222)
Other, net of effects of acquisitions (75) (586)
--------- ---------
16,369 18,129
Tax benefits from exercise of stock options 1,923 275
--------- ---------
Net cash provided by operating activities 18,292 18,404
--------- ---------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (5,080) (9,631)
Cash paid for acquisitions, net of cash acquired -- (5,572)
Advances under finance loans (1,010) (6,509)
Proceeds from finance loan repayments 3,277 --
Purchases of investments (17,325) (9,832)
Proceeds from sale of investments 13,250 28,657
--------- ---------
Net cash used in investing activities (6,888) (2,887)
--------- ---------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options 2,645 719
Proceeds from employee stock purchase plan 503 561
Purchase of treasury stock (10,133) (15,323)
--------- ---------
Net cash (used in) financing activities (6,985) (14,043)
--------- ---------
Effect of exchange rate changes on cash (52) --
--------- ---------
NET INCREASE IN CASH AND CASH EQUIVALENTS 4,367 1,474
CASH AND CASH EQUIVALENTS, beginning of the period 1,787 4,165
--------- ---------
CASH AND CASH EQUIVALENTS, end of the period $ 6,154 $ 5,639
========= =========
The accompanying notes are an integral part of
these condensed consolidated financial statements.
5
ICU MEDICAL, INC.
Condensed Consolidated Statements of Comprehensive Income
For the Three Months and Nine Months Ended
September 30, 2004 and September 30, 2003
(all dollar amounts in thousands)
(unaudited)
For the Three Months Ended For the Nine Months Ended
-------------------------- -------------------------
9/30/04 9/30/03 9/30/04 9/30/03
-------- -------- -------- --------
Net income (loss) $(1,036) $ 4,175 $ 6,514 $15,144
Other comprehensive income (loss) net of tax:
Foreign currency translation adjustment 49 -- (52) --
-------- -------- -------- --------
Comprehensive income (loss) $ (987) $ 4,175 $ 6,462 $15,144
======== ======== ======== ========
The accompanying notes are an integral part of
these condensed consolidated financial statements.
6
ICU MEDICAL, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2004
(All dollar amounts in tables in thousands except per share data)
(unaudited)
NOTE 1: BASIS OF PRESENTATION: The accompanying unaudited interim condensed
consolidated financial statements have been prepared in accordance with
accounting principles generally accepted in the United States of America and
pursuant to the rules and regulations of the Securities and Exchange Commission
and reflect all adjustments, which consist of only normal recurring adjustments,
which are, in the opinion of Management, necessary to a fair statement of the
consolidated results for the interim periods presented. Results for the interim
period are not necessarily indicative of results for the full year. Certain
information and footnote disclosures normally included in annual consolidated
financial statements prepared in accordance with generally accepted accounting
principles have been condensed or omitted pursuant to such rules and
regulations. The condensed consolidated financial statements should be read in
conjunction with the consolidated financial statements and notes thereto
included in our 2003 Annual Report to Stockholders.
ICU Medical, Inc. (the "Company," a Delaware corporation) operates
principally in one business segment engaged in the development, manufacturing
and marketing of disposable medical connection systems for use in intravenous
("I.V.") therapy applications designed to protect healthcare workers and
patients from the spread of infectious diseases. The Company's devices are sold
principally to distributors and medical product manufacturers throughout the
United States and a small portion internationally. All subsidiaries are wholly
or majority owned and are included in the consolidated financial statements. All
intercompany balances and transactions have been eliminated.
NOTE 2: INVENTORIES consisted of the following:
9/30/04 12/31/03
------- --------
Raw material $ 4,675 $ 2,699
Work in process 459 340
Finished goods 4,423 359
---------- ----------
Total $ 9,557 $ 3,398
========== ==========
NOTE 3: PROPERTY AND EQUIPMENT, at cost, consisted of the following:
9/30/04 12/31/03
------- --------
Land, building and building
improvements $ 21,755 $ 16,887
Machinery and equipment 30,244 26,429
Furniture and fixtures 7,620 6,572
Molds 9,746 11,480
Construction in process 4,196 10,247
---------- ----------
Total $ 73,561 $ 71,615
========== ==========
7
NOTE 4: FINANCE LOANS RECEIVABLE are commercial loans by ICU Finance, Inc., a
wholly-owned consolidated subsidiary. Loans are made only to credit-worthy
healthcare entities and are fully secured by real and personal property. The
Company plans to hold the loans to maturity or payoff. They are carried at their
outstanding principal amount, and will be reduced for an allowance for credit
losses and charge offs if any such reductions are determined to be necessary in
the future. Interest is accrued as earned based on the stated interest rate and
amounts outstanding. Loan fees and costs have not been material. Scheduled
maturities are: remainder of 2004 $312,000; 2005 $2,719,000; 2006 $1,181,000;
2007 $1,157,000 and 2008 $1,271,000. Weighted average maturity (principal and
interest) at September 30, 2004 was 1.4 years and the weighted average interest
rate was 5.4%. In October 2003, the Company discontinued new lending activities;
the Company will honor existing lending commitments. The maximum that can be
borrowed under all commitments, including amounts outstanding, was approximately
$6,748,000 at September 30, 2004.
NOTE 5: NET INCOME (LOSS) PER SHARE is computed by dividing net income by the
weighted average number of common shares outstanding. Diluted earnings per share
is computed by dividing net income by the weighted average number of common
shares outstanding plus dilutive securities, except in a loss period, when such
securities are excluded because they would decrease the diluted loss per share.
Dilutive securities are outstanding common stock options (excluding stock
options with an exercise price in excess of the average market value for the
period), less the number of shares that could have been purchased with the
proceeds from the exercise of the options, using the treasury stock method, and
were 1,201,323 for the three months ended September 30, 2003 and 1,265,058 and
1,282,918 for the nine months ended September 30, 2004 and 2003, respectively.
Potentially dilutive shares from common stock options excluded because of the
net loss for the three months ended September 30, 2004 were 1,107,914. Options
that are antidilutive because their average exercise price exceeded the average
market price of its common stock for the period approximated 1,400,000 and
810,000 for the three months ended September 30, 2004 and 2003 respectively and
850,000 and 555,000 for the nine months ended September 30, 2004 and 2003,
respectively.
NOTE 6: STOCK OPTIONS: The Company accounts for stock options granted to
employees and directors under Accounting Principles Board ("APB") Opinion No. 25
"Accounting for Stock Issued to Employees" and related interpretations as
permitted by SFAS No. 123 "Accounting for Stock-Based Compensation," and does
not recognize compensation expense because the exercise price of the options
equals the fair market value of the underlying shares at the date of grant.
Under SFAS No. 123, the Company is required to present certain pro forma
earnings information determined as if employee stock options were accounted for
under the fair value method of that Statement. The fair value for options
granted in the second quarter of 2004 and 2003 was estimated as of the date of
grant using a Black-Scholes option pricing model. The Black-Scholes option
valuation model was developed for use in estimating fair value of fully
transferable traded options with no vesting restrictions, and, similar to other
option valuation models, requires use of highly subjective assumptions,
including expected stock price volatility. The characteristics of its stock
options differ substantially from those of traded stock options, and changes in
the subjective assumptions can materially affect estimated fair values;
therefore, in Management's opinion, existing option valuation models do not
necessarily provide a reliable single measure of the fair value of its stock
options. The following information is provided pursuant to SFAS No. 123, as
amended.
8
The pro forma adjustment reflects stock-based compensation cost
calculated under the fair value method, net of related tax effects, calculated
pursuant to SFAS No. 123.
Quarter Ended Nine Months Ended
------------- -----------------
September 30, September 30,
------------- -------------
2004 2003 2004 2003
---------- ---------- ---------- -----------
Net income (loss), as reported .... ($ 1,036) $ 4,175 $ 6,514 $ 15,144
Pro forma adjustment .............. ((1,480) (1,224) (4,153) (3,863)
---------- ---------- ---------- -----------
Net income (loss), pro forma ...... ($ 2,516) $ 2,951 $ 2,361 $ 11,281
========== ========== ========== ===========
Net income (loss)per share
Basic, as reported ..... ($ 0.08) $ 0.31 $ 0.47 $ 1.10
Diluted, as reported ... ($ 0.08) $ 0.28 $ 0.43 $ 1.00
Basic, pro forma ....... ($ 0.18) $ 0.22 $ 0.17 $ 0.84
Diluted, pro forma ..... ($ 0.18) $ 0.20 $ 0.16 $ 0.76
NOTE 7: INCOME TAXES: The effective tax rate differs from that computed at the
federal statutory rate of 35% principally because of the effect of state income
taxes partially offset by the effect of tax-exempt investment income and state
and federal tax credits.
NOTE 8: MAJOR CUSTOMERS: The Company had revenues equal to ten percent or
greater of total net revenues from one customer, Hospira, Inc. (formerly a part
of Abbott Laboratories), of 56% and 65% in the third quarters of 2004 and 2003,
respectively, and of 57% and 67% in the first nine months of 2004 and 2003,
respectively.
NOTE 9: COMMITMENTS AND CONTINGENCIES: The Company is from time to time involved
in various routine non-material legal proceedings, either as a defendant or
plaintiff, most of which are routine litigation in the normal course of
business. The Company believes that the resolution of the legal proceedings in
which it is involved will not have a material effect on its financial position
or results of operations.
In the normal course of business, the Company has made certain
indemnities, including indemnities to its officers and directors, to the maximum
extent permitted under Delaware law and intellectual property indemnities to
customers in connection with sales of its products. These indemnities do not
provide a maximum amount. The Company has not recorded any liability for these
in its financial statements and does not expect to incur any.
NOTE 10: ACQUISITIONS: In June 2003, the Company acquired the assets of two
affiliated manufacturers of intravenous therapy systems located in northern
Italy for a cash payment of approximately $4.6 million. Principal assets
acquired are assembly facilities and related equipment of $2,443,000 and
inventories of $1,110,000 and an agreement not to compete valued at
approximately $818,000. The acquired assets and related operating results are
included in the Company's consolidated financial statements since June 30, 2003.
The effect of this acquisition on the Company's financial statements is
immaterial.
In September 2004, the Company purchased an interest of approximately
57% in a company developing a new medical device for use in screening for heart
disease for approximately $2.5 million in cash. The Company has agreed to invest
an additional $1.5 million if certain milestones are achieved by November 30,
2005. The company had no operations prior to the investment. Its only asset is
technology related to the device, which will require pre-market submission to
the Food and Drug Administration. The company is included in the consolidated
financial statements since September 2004, and the interests of the other
stockholders, who are the founders, are shown as minority interest.
Approximately $1.2 million of the Company's investment was allocated to
in-process research and development, based in part on an independent appraisal,
and that amount was charged to research and development expense in the Company's
consolidated financial statements in September 2004. The pro forma effects of
this acquisition were not significant.
9
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
We are a leader in the development, manufacture and sale of
proprietary, disposable medical connection systems for use in intravenous
("I.V.") therapy applications. Our devices are designed to protect healthcare
workers and their patients from exposure to infectious diseases such as
Hepatitis B and C and Human Immunodeficiency Virus ("HIV") through accidental
needlesticks. We are also a leader in the production of custom I.V. systems and
low cost generic I.V. systems and we incorporate our proprietary products on
many of those custom I.V. systems.
THIRD QUARTER OF 2004 AND RESULTS FOR THE YEAR 2004
The Company reported a loss for the quarter ended September 30, 2004
and expects to report a loss for the fourth quarter of 2004, although it does
expect to remain profitable for the full year 2004. The loss in the third
quarter is principally because Hospira, Inc., ("Hospira", formerly the Hospital
Products Division of Abbott Laboratories) decreased the level of purchases
because it is making a substantial reduction in its inventories of our products;
our sales to Hospira declined $7.5 million from the third quarter of 2003, and
$6.6 million of that decline was in CLAVE products. Because of the reduced sales
to Hospira, we curtailed our production of CLAVE products; but, since much of
our manufacturing costs are fixed, the reduced production resulted in unabsorbed
overhead of approximately $2.2 million. Total unabsorbed overhead for the third
quarter was approximately $2.9 million. We expect Hospira's purchases to
continue to decline in the fourth quarter of 2004 because we expect this
inventory reduction by Hospira to continue through the fourth quarter of 2004.
This will cause further reduction in production levels and somewhat greater
unabsorbed overhead in the fourth quarter of 2004. Although Hospira is reducing
its purchases, information provided by Hospira indicates that Hospira's unit
sales of CLAVE products to its customers have continued to increase, and we
further believe that once Hospira reduces its inventory to the desired level,
our sales of CLAVE products to Hospira will more closely match its sales to its
customers than they have in the past. Our inventory of CLAVE products is higher
than normal at September 30, 2004; we expect reduced production levels and
unabsorbed overhead to continue into early 2005.
Sales of our Punctur-Guard products declined from $1.7 million in the
third quarter of 2003 to $0.5 million in the third quarter of 2004. We have
experienced lower unit volumes and have reduced prices to achieve wider
distribution. While we expect sales increases in Punctur-Guard products in the
fourth quarter of 2004, there is no assurance that any such increases will be
realized and if they are not, most of the unabsorbed overhead will continue.
In September 2004, we invested approximately $2.5 million in a
company developing a new medical device. Approximately $1.2 million of the
Company's investment was allocated to in-process research and development, and
that amount, which is non-recurring, was charged to research and development
expense in the Company's consolidated financial statements in September 2004.
Our operating expenses (including research and development) increased
approximately $2.8 million in the third quarter of 2004 as compared to the third
quarter of 2003. This was principally because of the $1.2 million expense of
in-process research and development mentioned above, patent litigation costs,
costs related to Sarbanes-Oxley compliance, and increased information technology
costs.
10
In summary, in millions of dollars:
Income from operations, three months ended 9/30/03 $ 6.5
Sales reduction from $25.0 to $15.9: approximate effect on standard gross profit (4.9)
Unabsorbed overhead $2.9 million in excess of $2.0 million in 2003 (0.9)
Increased operating expenses (including in-process R&D) (2.8)
------
Loss from operations, three months ended 9/30/04 $(2.1)
======
CRITICAL ACCOUNTING POLICIES
Our significant accounting policies are summarized in Note 1 to the
Consolidated Financial Statements included in our 2003 Annual Report to
Shareholders. In preparing our financial statements, we make estimates and
assumptions that affect the expected amounts of assets and liabilities and
disclosure of contingent assets and liabilities. We apply our accounting
policies on a consistent basis. As circumstances change, they are considered in
our estimates and judgments, and future changes in circumstances could result in
changes in amounts at which assets and liabilities are recorded.
Investment securities are all marketable and considered "available
for sale". See Item 3. Quantitative and Qualitative Disclosures about Market
Risk. Under our current investment policies, the securities in which we invest
have no significant difference between cost and fair value. If our investment
policies were to change, and there were differences between cost and fair value,
that difference, net of tax effect, would be reflected as a separate component
of stockholders' equity.
We record sales and related costs when ownership of the product
transfers to the customer. Under the terms of most purchase orders, ownership
transfers on shipment, but in some cases it transfers on delivery. If there are
significant doubts at the time of shipment as to the collectibility of the
receivable, we defer recognition of the sale in revenue until the receivable is
collected. Most of our customers are medical product manufacturers or
distributors, although some are end-users. Our only post-sale obligations are
warranty and certain rebates. We warrant products against defects and have a
policy permitting the return of defective products. We record warranty returns
as an expense and amounts have been insignificant. Customers, with certain
exceptions, do not retain any right of return and there is no price protection
with respect to unsold products; returns from customers with return rights have
not been significant. We accrue rebates as a reduction in revenue based on
contractual commitments and historical experience. Adjustments of estimates of
warranty claims, rebates or returns, which have not been, and are not expected
to be material, affect current operating results when they are determined.
Accounts receivable are stated at net realizable value. An allowance
is provided for estimated collection losses based on specific past due accounts
for which we consider collection to be doubtful. Loss exposure is principally
with international distributors for whom normal payment terms are long in
comparison to those of our other customers and, to a lesser extent, domestic
distributors. Many of these distributors are relatively small and we are
vulnerable to adverse developments in their businesses that can hinder our
collection of amounts due. If actual collection losses exceed expectations, we
could be required to accrue additional bad debt expense, which could have an
adverse effect on our operating results in the period in which the accrual
occurs.
Inventories are stated at the lower of cost or market. We need to
carry many components to accommodate our rapid product delivery, and if we
misestimate demand or if customer requirements change, we may have components in
inventory that we may not be able to use. Most finished products are made only
after we receive orders except for certain standard (non-custom) products which
11
we will carry in inventory in expectation of future orders. For finished
products in inventory, we need to estimate what may not be saleable. We
regularly review inventory for slow moving items and write off all items we do
not expect to use in manufacturing, or finished products we do not expect to
sell. If actual usage of components or sales of finished goods inventory is less
than our estimates, we would be required to write off additional inventory,
which could have an adverse effect on our operating results in the period in
which the write-off occurs.
Property and equipment is carried at cost and depreciated on the
straight-line method over the estimated useful lives. The estimates of useful
lives are significant judgments in accounting for property and equipment,
particularly for molds and automated assembly machines that are custom made for
us. We may retire them on an accelerated basis if we replace them with larger or
more technologically advanced tooling. The remaining useful lives of all
property and equipment are reviewed regularly and lives are adjusted or assets
written off based on current estimates of future use. As part of that review,
property and equipment is reviewed for other indicators of impairment, but to
date we have not encountered circumstances indicating the carrying amount of an
asset, or group of assets, may not be recoverable. An unexpected shortening of
useful lives of property and equipment that significantly increases depreciation
provisions, or other circumstances causing us to record an impairment loss on
such assets, could have an adverse effect on our operating results in the period
in which the related charges are recorded.
NEW ACCOUNTING PRONOUNCEMENTS
We have implemented all new accounting pronouncements that are in
effect and that may impact our consolidated financial statements and do not
believe that there are any other new accounting pronouncements that have been
issued that might have a material impact on our consolidated financial
statements.
BUSINESS OVERVIEW
Until the late 1990s, our primary emphasis in product development,
sales and marketing was disposable medical connectors for use in I.V. therapy,
and our principal product was the CLAVE. In the late 1990s, we commenced a
transition from a product-centered company to an innovative, fast, efficient,
low-cost manufacturer of custom I.V. systems, using processes that we believe
can be readily applied to a variety of disposable medical devices. This strategy
enables us to capture revenue on the entire I.V. system, and not just a
component of the system.
We are also increasing our efforts to acquire new products. We
acquired the Punctur-Guard line of blood collection needles in 2002, invested in
a company developing a new medical device in 2004, and are continuing to seek
other opportunities. However, there can be no assurance that we will be
successful in finding acquisition opportunities, or in acquiring companies or
products.
Custom I.V. systems and new products will be of increasing importance
to us in future years. We expect CLAVE products will grow in 2005 in the U.S.,
but at a slower percentage growth rate than in the past because of our large
market penetration and potentially substantial increases in competition if we
are unsuccessful in enforcing our intellectual property rights. Growth for all
of our products outside the U.S. could be substantial, although to date it has
been modest. Therefore, we will be directing increasing product development,
acquisition, sales and marketing efforts to custom I.V. systems and new products
in the U.S. and increasing our emphasis on the markets outside the U.S.
Our largest customer has been Abbott Laboratories ("Abbott"). On
April 30, 2004, Abbott spun off its core Hospital Products Division to its
stockholders as an independent company named Hospira, Inc. The Hospital Products
Division historically accounted for virtually all of our sales to Abbott. Abbott
has assigned our agreements with Abbott to Hospira. We believe the spin-off is a
positive development for us and will result in new business opportunities with
Hospira. For clarity, all historical references to Abbott and its Hospital
Products Division have been changed to Hospira.
12
Our relationship with Hospira has been and will continue to be of
singular importance to our growth. In 2003, approximately 67% of our revenue was
from sales to Hospira. For the nine months ended September 30, 2004,
approximately 56% of our revenue was from sales to Hospira. We expect this
percentage of revenue to decrease in the fourth quarter of 2004 compared with
2003, as Hospira continues to reduce their amount of CLAVE products inventory.
However, we expect it to return to approximately the level of 2003 when Hospira
resumes normal purchases of our products in 2005. Hospira has a significant
share of the I.V. set market in the U.S., and provides us access to that market.
We expect that Hospira will be important to our growth for CLAVE, custom I.V.
systems, and our other products in the U.S. and also outside the U.S.
We believe that achievement of our growth objectives, both within the
U.S., and outside the U.S., will require increased efforts by us in sales and
marketing and product development, and we have started increasing expenditures
for those during 2004.
There is no assurance that we will be successful in implementing our
growth strategy. The custom I.V. systems market is still small and we could
encounter customer resistance to custom products. Further, we could encounter
increased competition as other companies see opportunity. Product development or
acquisition efforts may not succeed, and even if we do develop or acquire
products, there is no assurance that we will achieve profitable sales of such
products. An adverse change in our relationship with Hospira, or a deterioration
of Hospira's position in the market, could have an adverse effect on us.
Increased expenditures for sales and marketing and product acquisition and
development may not yield desired results when expected, or at all. While we
have taken steps to control all these risks, there are certain of those risks
which may be outside of our control, and there is no assurance that steps we
have taken will succeed.
OVERVIEW OF OPERATIONS
The following table sets forth the net revenues by product as a
percentage of total net sales for the periods indicated:
==================================== ============ ============ =========== ============ =========== ============ ============
YTD YTD
PRODUCT LINE 2001 2002 2003 Q3-03 Q3-04 Q3-03 Q3-04
- ------------------------------------ ------------ ------------ ----------- ------------ ----------- ------------ ------------
CLAVE 74% 67% 59% 55% 47% 58% 49%
- ------------------------------------ ------------ ------------ ----------- ------------ ----------- ------------ ------------
Custom and Generic I.V. Systems 13% 17% 22% 26% 39% 21% 33%
- ------------------------------------ ------------ ------------ ----------- ------------ ----------- ------------ ------------
Punctur-Guard(R) - 1% 7% 6% 3% 6% 5%
- ------------------------------------ ------------ ------------ ----------- ------------ ----------- ------------ ------------
CLC2000(R) 3% 4% 4% 4% 3% 4% 4%
- ------------------------------------ ------------ ------------ ----------- ------------ ----------- ------------ ------------
Other Products 10% 7% 4% 7% 5% 6% 6%
- ------------------------------------ ------------ ------------ ----------- ------------ ----------- ------------ ------------
License, royalty and revenue share - 4% 4% 2% 3% 5% 3%
- ------------------------------------ ------------ ------------ ----------- ------------ ----------- ------------ ------------
Total 100% 100% 100% 100% 100% 100% 100%
==================================== ============ ============ =========== ============ =========== ============ ============
Most custom I.V. systems include one or more CLAVEs. Total CLAVE
sales including custom I.V. systems with at least one CLAVE were 73% of net
revenue in the third quarter of 2003 and 76% of net revenue in the third quarter
of 2004, and 73% and 72% year-to-date September 30, 2003 and 2004, respectively.
13
We sell our products to independent distributors and through
agreements with Hospira (the "Hospira Agreements") and certain other medical
product manufacturers. Most independent distributors handle the full line of our
products. Hospira purchases CLAVE products, principally bulk, non-sterile
connectors, and the CLC2000. In addition, we sell custom I.V. systems to Hospira
under a program referred to as SetSource. In January 2004, we announced the
execution of amendments to our existing agreements with Hospira. The amendments
extend the terms of our agreements to 2014 and provide Hospira with rights to
distribute all existing ICU Medical products worldwide. We signed another
contract amendment with Hospira in January 2004 to distribute our Punctur-Guard
line of blood collection needles in the U.S. and the rest of the world. We also
sell certain other products to a number of other medical product manufacturers.
We believe that as healthcare providers continue to either
consolidate or join major buying organizations, our success in marketing and
distributing CLAVE products will depend, in part, on our ability, either
independently or through strategic relationships such as our Hospira
relationship, to secure long-term CLAVE contracts with large healthcare
providers and major buying organizations. As a result of this marketing and
distribution strategy we derive most of our revenues from a relatively small
number of distributors and manufacturers. The loss of a strategic relationship
with a customer or a decline in demand for a manufacturing customer's products
could have a material adverse effect on our operating results.
In June 2004, Cardinal Health, Inc. ("Cardinal") acquired Alaris
Medical Systems, Inc. ("Alaris"). Alaris manufactures a connector that competes
with the CLAVE. Cardinal is the largest distributor of healthcare products in
the United States, and the companies have announced their intent to increase
market share growth beyond what Alaris might be able to achieve on its own. We
believe the ownership of Alaris by Cardinal could adversely affect our market
share and the prices for our CLAVE products.
We believe the success of the CLAVE has motivated, and will continue
to motivate others to develop one-piece, swabbable, needleless connectors that
may incorporate many of the same functional and physical characteristics as the
CLAVE. We are aware of a number of such products. We have patents covering the
technology embodied in the CLAVE and intend to enforce those patents as
appropriate. If we are not successful in enforcing our patents, competition from
such products could adversely affect our market share and prices for our CLAVE
products. In response to competitive pressure, we have been reducing prices to
protect and expand our market, although overall pricing has been stable
recently. The price reductions to date have been more than offset by increased
volume after excluding the effect of Hospira's inventory reductions in 2004. We
expect that the average price of our CLAVE products may continue to decline.
There is no assurance that our current or future products will be able to
successfully compete with products developed by others.
The federal Needlestick Safety and Prevention Act, enacted in
November 2000, modified standards promulgated by the Occupational Safety and
Health Administration to require employers to use safety I.V. systems where
appropriate to reduce risk of injury to employees from needlesticks. We believe
this law has had and will continue to have a positive effect on sales of our
needleless systems and blood collection needles, although we are unable to
quantify the current or anticipated effect of the law on our sales.
We are taking steps to reduce our dependence on our current
proprietary products. We are seeking to substantially expand our custom I.V.
systems business through increased sales to medical product manufacturers and
independent distributors. Under one of our Hospira Agreements, we manufacture
all new custom I.V. sets for sale by Hospira and jointly promote the products
under the name SetSource. We expect continuing yearly increases in sales of
custom I.V. systems under this agreement. We also contract with group purchasing
organizations and independent dealer networks for inclusion of our products
among those available to members of those entities. Custom I.V. systems
accounted for approximately $20.0 million of net sales in the first nine months
14
of 2004, including net sales under the Hospira SetSource program of
approximately $8.9 million. Also, in the fourth quarter of 2002 we acquired
Bio-Plexus. Inc. ("Bio-Plexus"), whose principal products are blood collection
needles, under the Punctur-Guard name, that are designed to eliminate exposure
to sharp, contaminated needles. Punctur-Guard product revenues in the first nine
months of 2004 were $3.1 million. In 2004, we invested in a company developing a
new medical device; sales depend on the success of efforts to develop and market
the device, and there can be no certainty that those efforts will succeed. There
is no assurance that any of these initiatives will continue to succeed.
We have an ongoing program to increase systems capabilities, improve
manufacturing efficiency, reduce labor costs, reduce time needed to produce an
order, and minimize investment in inventory. These include use of automated
assembly equipment for new and existing products, use of larger molds and
molding machines, centralization of all proprietary molding in San Clemente,
expansion of our production facility in Mexico, and the establishment of other
production facilities outside the U.S.
We distribute products through three distribution channels. Net
product revenues for each distribution channel were as follows:
==================================== =========== ============ ============ ============ ============ ============ ============
CHANNEL YTD YTD
2001 2002 2003 Q3-03 Q3-04 Q3-03 Q3-04
- ------------------------------------ ----------- ------------ ------------ ------------ ------------ ------------ ------------
Medical product manufacturers 72% 73% 71% 68% 58% 72% 59%
- ------------------------------------ ----------- ------------ ------------ ------------ ------------ ------------ ------------
Independent domestic distributors 20% 19% 23% 25% 32% 23% 30%
- ------------------------------------ ----------- ------------ ------------ ------------ ------------ ------------ ------------
International 8% 8% 6% 7% 10% 5% 11%
- ------------------------------------ ----------- ------------ ------------ ------------ ------------ ------------ ------------
Total 100% 100% 100% 100% 100% 100% 100%
==================================== =========== ============ ============ ============ ============ ============ ============
QUARTER-TO-QUARTER COMPARISONS: We present summarized income
statement data in Item 1. Financial Statements. The following table shows, for
the year 2003 and the third quarter and first nine months of 2003 and 2004, the
percentages of each income statement caption in relation to revenues, and the
percentage change in each caption in each quarter. (We currently calculate our
gross profit percentage based on net sales, which includes only product sales
and excludes non-product revenue such as license fees. See below for information
on non-product revenue. We present the alternative calculation based on total
revenue for the convenience of readers who prefer to view it that way.)
15
Percentage of Revenues
----------------------------------------------------------------------------
Year Quarter ended Nine months ended
September 30, September 30,
--------- ----------------------------- -----------------------------
2003 2003 2004 CHANGE 2003 2004 CHANGE
---- ---- ---- ------ ---- ---- ------
Revenue
Net sales 96% 98% 97% -36% 95% 96% -21%
Other 4% 2% 3% 13% 5% 4% -45%
--------- --------- --------- --------- --------- --------- ---------
Total revenues 100% 100% 100% -36% 100% 100% -22%
Cost of sales 47% 52% 60% -25% 46% 49% -17%
Gross Profit
Percentage of net sales 53% 47% 37% -50% 52% 50% -25%
Percentage of all revenues 55% 48% 40% -47% 54% 51% -26%
Selling, general and administrative expenses 21% 21% 41% 26% 22% 32% 12%
Research and development expenses 2% 2% 11% 321% 1% 4% 83%
--------- --------- --------- --------- --------- --------- ---------
Total operating expenses 23% 23% 52% 48% 23% 36% 18%
Income (loss) from operations 32% 25% -12% -132% 31% 18% -61%
--------- --------- --------- --------- --------- --------- ---------
Investment income 1% 1% 2% -20% 1% 2% 23%
--------- --------- --------- --------- --------- --------- ---------
Income (loss) before income taxes 33% 26% -10% -125% 32% 17% -58%
Income taxes 12% 10% -4% -124% 12% 6% -59%
--------- --------- --------- --------- --------- --------- ---------
Net income (loss) 21% 16% -6% -125% 20% 11% -57%
========= ========= ========= ========= ========= ========= =========
QUARTERLY RESULTS: The healthcare business in the United States is
subject to seasonal fluctuations, and activity tends to diminish somewhat in the
summer months of June, July and August, when illness is less frequent than in
winter months and patients tend to postpone elective procedures. This typically
causes seasonal fluctuations in our business. In addition, we can experience
fluctuations in net sales as a result of variations in the ordering patterns of
our largest customers, which may be driven more by production scheduling and
their inventory levels, and less by seasonality. Our expenses often do not
fluctuate in the same manner as net sales, which may cause fluctuations in
operating income that are disproportionate to fluctuations in our revenue.
QUARTER ENDED SEPTEMBER 30, 2004 COMPARED TO THE QUARTER ENDED SEPTEMBER 30,
- ----------------------------------------------------------------------------
2003
- ----
Net revenues decreased $9,056,000, or approximately 36%, to
$16,468,000 in the third quarter of 2004, compared to $25,524,000 during the
same period last year.
DISTRIBUTION CHANNELS: Net sales to Hospira in the third quarter of
2004 were $8,833,000, as compared with net sales of $16,370,000 in the third
quarter of 2003. (Hospira sales discussed in this paragraph do not include
export and foreign sales.) Net sales of CLAVE Products to Hospira, excluding
custom CLAVE I.V. systems, decreased by $6,630,000 to $5,281,000 in the third
quarter of 2004 from $11,911,000 in the third quarter of 2003 primarily because
Hospira has decreased its level of purchases because it is making a substantial
reduction in its inventory of CLAVE products. Although Hospira is reducing its
purchases, information provided by Hospira indicates that Hospira's CLAVE unit
sales to their customers have increased in this period. Sales to Hospira under
the SetSource program approximated $3,138,000 in the third quarter of 2004 as
16
compared with approximately $3,096,000 in the third quarter of 2003, a 1%
increase. We expect a decrease in CLAVE unit and dollar sales volume with
Hospira through the balance of 2004 as compared to the third quarter of 2004 as
Hospira continues to reduce its inventory. We expect the past significant
increases in SetSource unit and sales volume to slow down for the remainder of
2004 as compared to 2003 as Hospira's sales personnel focus more of their sales
efforts on Hospira's I.V. pumps; we believe the effect of this will be
temporary. Net sales of CLC2000 decreased to virtually none in the third quarter
of 2004 because Hospira has also been reducing its inventory of CLC2000
products. There is no assurance as to the amount of any future sales increases
to Hospira.
Net sales to independent domestic distributors decreased
approximately 22% from $6,491,000 in the third quarter of 2003 to $5,086,000 in
2004. The decrease in sales to independent distributors is attributed
principally to an $816,000 or 51% decrease in Punctur-Guard product sales and a
$450,000 or 14% decrease in sales of Custom I.V. systems. The decrease in sales
of Punctur-Guard products is primarily due to a reduction in average sales price
to achieve a wider distribution. We also experienced a loss of some customers
and unit volume on the Punctur-Guard products while making changes for a more
marketable product. We believe that the decrease in sales of custom I.V systems
is primarily due to seasonal factors mentioned above. We anticipate an increase
of Punctur-Guard unit and dollar volumes in the future through new outpatient
provider contracts, coupled with new distribution focused on the lab market. As
part of our program to increase sales of custom I.V. systems, we have been
encouraging customers to purchase custom I.V. systems that include CLAVE
connectors, rather than purchasing only the CLAVE connectors. There is no
assurance as to the amount of any future sales increases to the independent
domestic distributors.
Net sales to international distributors (excluding Canada) were
$1,586,000 in the third quarter of 2004, as compared with $1,649,000 in the
third quarter of 2003. The decrease was primarily comprised of a $457,000
decrease in sales or Punctur-Guard products, offset by a $319,000 increase in
custom I.V. system sales. We expect increases in foreign sales in the future in
response to increased sales and marketing efforts including adding additional
business development managers. Also, we believe we will see a positive impact in
2005 from our recent amendments to the Hospira contracts. There is no assurance
that those expectations will be realized.
PRODUCT AND OTHER REVENUE: Net sales of CLAVE Products (excluding
custom CLAVE I.V. systems) decreased to $7,722,000 in the third quarter of 2004
from $13,991,000 in the third quarter of 2003. This decrease was due primarily
to a decrease in unit shipments of CLAVE products to Hospira, partially offset
by an increase in unit shipments to our domestic and international distributors.
Sales of custom I.V. systems including one or more CLAVE connectors and CLAVE
products combined were $12,117,000 in the third quarter of 2004 as compared with
$18,715,000 in the third quarter of 2003, and the decrease caused by Hospira's
lower purchases of CLAVE products. We expect a decrease in CLAVE (not including
custom sets with CLAVE) unit and dollar volume in the fourth quarter of 2004 as
compared with the fourth quarter of 2003 because of the expected reduction in
inventory of CLAVE products by Hospira, partially offset by increased unit and
dollar volume with our domestic and our international distributors. However,
there is no assurance that these expectations will be realized.
Net sales of custom I.V. systems were $6,376,000 in the third quarter
of 2004 compared to $6,681,000 in the third quarter of 2003, a $305,000, or a 5%
decrease, principally due to the previously mentioned decline in custom I.V.
system sales through our domestic distributors.
We acquired the Punctur-Guard product line and technology with the
purchase of Bio-Plexus on October 31, 2002. After our acquisition of Bio-Plexus
on October 31, 2002, we made significant improvements to the Punctur-Guard
products and manufacturing processes. We did not actively promote sales of those
products until completion of those product improvements. We completed
improvements on the Winged Set products and re-launched them in mid 2003. We
completed initial improvements on the tubular blood collection needle and
started selling the improved product in late 2003. We completed additional
improvements to this product line in 2004. Sales of Punctur-Guard products
17
(excluding royalties) were $451,000 in the third quarter of 2004 as compared to
$1,652,000 in the third quarter of 2003 due to a decrease in unit sales and to
pricing concessions on our Punctur-Guard line of products to achieve wider
distribution. We anticipate increased unit and dollar volumes in the remainder
of 2004 over levels in the third quarter of 2004 through new outpatient provider
contracts, coupled with new distribution focused on the lab market, but we give
no assurance that such increases will be achieved.
Net sales of the CLC2000 were $568,000 in the third quarter of 2004,
a $486,000, or 46%, decrease from the third quarter of 2003 due to a decrease in
unit shipments to Hospira as they reduced purchases. We expect sales of the
CLC2000 to increase moderately after 2004, but there is no assurance as to the
amount or timing of future CLC2000 sales.
Other revenue consists of non-product revenue. The principal ongoing
components are royalties received for other companies' use of Punctur-Guard
technology, SafeLine revenue share payments from B. Braun and payments under
another license of approximately $235,000 per quarter for four years starting in
the first quarter of 2004. These ongoing components account for all of our other
revenue in the third quarters of 2003 and 2004. We may receive other license
fees or royalties in the future for the use of our technology. We give no
assurance as to amounts or timing of any future payments, or whether such
payments will be received.
GROSS MARGIN for the third quarter of 2004, calculated on net sales
and excluding other revenue, was 37% as compared to 47% for the third quarter of
2003. Our overall standard gross margins are approximately 57% (although they
can vary depending on product mix). In the third quarter of 2004, gross margins
were adversely affected by approximately 13 percentage points because of the
curtailment in production of CLAVE products because of reduced shipments to
Hospira, approximately 5 percentage points by Punctur-Guard operations, which
currently have a lower gross margin than most of our other products and which
were also adversely affected by reduced production levels, and the new facility
in Italy. In the third quarter of 2003, gross margins were adversely affected by
approximately 7 percentage points because of some non-recurring production
changes in our automated production in San Clemente and approximately 3
percentage points due to Punctur-Guard production. We believe that production in
San Clemente in the remainder of 2004 will be less than originally anticipated
because of the reduced purchases by Hospira as they reduce inventory levels.
This reduced production level and continuing lower margins on Punctur-Guard
products will continue to have an adverse impact on our gross margins. We are
working to improve gross margins on the Punctur-Guard products; improvement will
depend on increased sales and full conversion of this product line to our
manufacturing techniques. We give no assurance as to the amount or timing of
future improvements to our gross margins.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES ("SG&A") in the third
quarter of 2004 increased $1,420,000, or 26%, to $6,807,000, and was
approximately 41% of revenue in 2004 as compared with 21% of revenue in 2003.
The increase in costs was primarily due to increased corporate administrative
costs. These increased costs were primarily patent litigation costs, costs
related to Sarbanes-Oxley compliance and increased information technology costs.
We expect all these costs to continue at levels above those incurred in 2003.
Sales and marketing costs increased slightly because of the addition of
personnel, and we expect increased selling costs in the fourth quarter of 2004
as we add more sales personnel.
RESEARCH AND DEVELOPMENT EXPENSES ("R&D") increased in the third
quarter of 2004 by $1,344,000 over the $419,000 recorded in the third quarter of
2003, principally because of $1,154,000 of in-process R&D related to the
investment in a company developing a new medical device which was charged to R&D
expense in September 2004. The device is being designed for use in screening for
heart disease. The device in is the very early stage of design, uses new
technology, and completion of a marketable device is expected to take at least
several years at a cost somewhat in excess of the Company's current funding
commitment of up to $4 million; there is no assurance as to the timing of or
cost of completing a marketable device or whether it will be completed.
18
R&D expense was approximately 11% of revenues in the third quarter of
2004 as compared with approximately 2% in the third quarter of 2003. Other
spending was principally on new product development, with a smaller amount being
spent on product improvements to the Punctur-Guard line. Spending on software
development decreased as principal development projects neared completion. We
estimate that R&D costs will be 2% to 3% of revenue during the fourth quarter of
2004 to support ongoing new product development and various product and process
improvements. However, R&D costs could differ from these estimates and the R&D
may not be completed as expected.
We plan to launch, in limited markets, a new connector in the first
quarter of 2005. We have received approval to market this new connector from the
Food & Drug Administration ("FDA") under Section 510(k) of the Federal Food,
Drug and Cosmetics Act. We also expect to launch a new product for the diabetes
market for which we have also received marketing approval from the FDA under
section 510(k) and which we expect to introduce in the first half of 2005. We
are currently developing a new integral check valve for use with all standard
and custom I.V. administration sets, which we expect to go into production in
the first half of 2005. We plan to seek FDA marketing approval in 2005 for a new
product which we plan to introduce for use on custom I.V. sets in Europe. There
is no assurance that the FDA will grant any required marketing clearance, that
we will launch any of these new products, or that they will achieve sales if and
when we commence marketing them.
INVESTMENT INCOME increased in the third quarter of 2004 as compared
with the third quarter of 2003 by $62,000, because of an increase in invested
funds (including finance loans) and slight increase in overall yield.
INCOME TAXES were accrued at an effective tax rate of 37.5% in the
third quarter of 2004, as compared with 38.5% in the third quarter of 2003. The
tax rate decrease is principally because of savings in state income taxes due to
organizational changes.
NINE MONTHS ENDED SEPTEMBER 30, 2004 COMPARED TO THE NINE MONTHS ENDED
- ----------------------------------------------------------------------
SEPTEMBER 30, 2003
- ------------------
Net revenues decreased $17,217,000, or approximately 22%, to
$60,366,000 in the first nine months of 2004 compared to $77,583,000 during the
same period last year. Approximately $15.2 million of this decrease was because
of reduced purchases of our products (excluding SetSource products) by Hospira,
as they reduce inventory levels. An additional $6.7 million of the decrease is
attributable to two items that occurred in the first half of 2003 but did not
recur in 2004: a deferment of approximately $4.0 million of CLAVE product
available for delivery to Hospira on current orders in the fourth quarter of
2002, but for which shipment was deferred until early 2003 by agreement with
Hospira, and a one-time license fee of approximately $2.7 million; an additional
$0.6 million of the decrease was from lower sales to domestic distributors.
Those decreases were partially offset by a $1.4 million increase in sales of
SetSource products to Hospira, a $2.9 million increase in sales to international
distributors and a $1.0 million increase in recurring non-product revenue.
DISTRIBUTION CHANNELS: Net sales to Hospira in the first nine months
of 2004 were $33,313,000, as compared with net sales of $51,121,000 in the first
nine months of 2003. Net sales of CLAVE Products to Hospira, excluding custom
CLAVE I.V. systems decreased to $21,641,000 in the first nine months of 2004
from $39,609,000 in the first nine months of 2003 principally due to a decrease
in unit volume as Hospira reduced its inventory of CLAVE products and in part
because there was nothing comparable in 2004 to the deferment of approximately
$4,000,000 of CLAVE orders to the first quarter of 2003. Information provided by
Hospira indicates their unit sales to their customers have increased in the
first nine months of 2004. Sales to Hospira under the SetSource program
approximated $8,935,000 in the first nine months of 2004 as compared with
$7,544,000 in the first nine months of 2003 on increased unit volume.
Net sales to independent domestic distributors decreased
approximately $645,000, or 4%, from $17,909,000 in the first three quarters of
2003 to $17,263,000. Independent domestic distributors had a 3%, or $114,000,
increase in CLAVE product sales principally because of an increase in unit
volume. Custom I.V. system sales increased 13% from approximately $7,697,000 to
19
approximately $8,798,000 (this includes all custom I.V. systems, including
custom I.V. systems that include CLAVE connectors). The increase in sales of
custom I.V. systems was attributable to an increase in unit volume. Those
increases were more than offset by a $1,522,000, or 32%, decrease in sales of
Punctur-Guard products due to a decrease in unit sales and to pricing
concessions on our Punctur-Guard line of products to achieve wider distribution;
and, a decrease in sales of CLC2000 of 33% on lower unit volume.
Net sales to international distributors (excluding Canada) were
$6,412,000 in the first nine months of 2004, as compared with $3,469,000 in the
first nine months of 2003. The increase was principally due to a $1,779,000
increase in CLAVE product sales and a $442,000 increase in custom I.V. set
sales. In 2003, we experienced a slowing of distributor orders while they
reduced CLAVE inventory levels. Orders in most areas of the world have returned
to more normal levels, and this and expansion of our business accounted for the
increase in CLAVE sales. The increase in sales of custom I.V. systems was
attributable to an increase in unit volume.
PRODUCT AND OTHER REVENUE: Net sales of CLAVE Products (excluding
custom CLAVE I.V. systems) decreased from $45,044,000 in the first nine months
of 2003 to $29,678,000 in the first nine months of 2004, or 34%. CLAVE product
sales to Hospira decreased $17,969,000, as Hospira decreased its level of
purchases because it is making a substantial reduction in its inventory of CLAVE
products. That decrease was partially offset by increases in CLAVE product sales
to independent domestic and international distributors.
Net sales of custom and generic I.V. systems increased approximately
$2,878,000, or 18%, to $19,967,000 in the first nine months of 2004 over the
first nine months of 2003. The SetSource program with Hospira accounted for
about $1,392,000 of the increase, and domestic distributors accounted for
$1,002,000, and international distributors accounted for the remaining increase.
Unit volume accounted for the majority of the increase. Sales of custom I.V.
systems including one or more CLAVE connectors and CLAVE products combined were
$43,385,400 in the first nine months of 2004 as compared with $56,484,000 in the
first nine months of 2003. The decrease was attributable to a decrease in
Hospira's purchase of CLAVE products partially offset by increases in CLAVE
product sales in all other channels and increases in sales of custom I.V.
systems including one or more CLAVE in all channels.
Net sales of Punctur-Guard products (excluding royalties) were
$3,100,000 in the first nine months of 2004 as compared to $5,004,000 in the
first nine months of 2003. The decrease was due to a decrease in unit sales and
to pricing concessions on our Punctur-Guard line of products to achieve wider
distribution.
Net sales of CLC2000 in the first nine months of 2004 decreased 17%
or $489,000 from the first nine months of 2003. This decrease is primarily due
to Hospira reducing its inventory of this product.
Other revenue consists of non-product revenue and was $2,200,000 in
the first nine months of 2004 compared to $3,967,000 in the first nine months of
2003. The principal ongoing components are royalties received for other
companies' use of Punctur-Guard technology, SafeLine revenue share payments from
B. Braun and payments under another license of approximately $235,000 per
quarter for four years starting in the first quarter of 2004. These ongoing
components account for all of our other revenue in 2004. The decrease in other
revenue from 2003 is because of a one-time license fees of $2.7 million received
in 2003 which did not recur in 2004, partially offset by increased recurring
payments in 2004.
GROSS MARGIN, calculated on net sales and excluding other revenue,
was 50% for the first nine months of 2004 as compared to 52% during the first
nine months of 2003. In 2003, the gross margin was adversely affected
principally by several non-recurring items and because of the effect of our
Punctur-Guard operations and the new facility in Italy. In 2004, the adverse
20
effect on margins of the Punctur-Guard operations increased, and depressed
year-to-date gross margins by approximately 5 percentage points. Also, in 2004,
the curtailment of production of CLAVE products because of reduced shipments to
Hospira depressed year-to-date gross margins by approximately 3 percentage
points.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES ("SG&A") increased by
$2,048,000 to $19,065,000, and were 32% of revenues in the first nine months of
2004, as compared with 22% in the first nine months of 2003 on higher revenue.
The increases in cost was primarily due to increased corporate administrative
costs, which was principally comprised of costs related to Sarbanes-Oxley
compliance and increased information technology costs. Other increases were in
sales and marketing. and integration and administrative costs related to our
operation in Italy, and these increases were partially offset by the elimination
of administrative costs related to Bio-Plexus.
RESEARCH AND DEVELOPMENT EXPENSES ("R&D") increased in the first nine
months of 2004 by $1,190,000 to $2,617,000, and were approximately 4% of
revenues in the first nine months of 2004. The increase is primarily comprised
of $1,154,000 of in-process R&D related to the investment in a company
developing a new medical device. This was charged to R&D in September 2004.
INCOME FROM OPERATIONS decreased $14,205,000, or 58%, principally
because of the decrease in net revenue, the resulting decrease in the gross
margin, the growth in operating expenses and the write-off of in-process R&D.
The operating margin was 15% of revenues in the first nine months of 2004 and
31% in the first nine months of 2003.
INVESTMENT INCOME increased $200,000, or 23%, as compared with the
first nine months of 2003, because of an increase in invested funds (including
finance loans) and a slight increase in overall yield.
INCOME TAXES were accrued at an effective tax rate of 37.5% in the
first nine months of 2004 as compared to 38.4% in the first nine months of 2003.
NET INCOME decreased $8,630,000, or 57%, to $6,514,000 as compared
with $15,144,000 for the first nine months of 2003 for the same reason income
from operations declined. NET INCOME PER SHARE - DILUTED decreased 57% to $0.43
per share in the first nine months of 2004 as compared with $1.00 for the first
nine months of 2003 on the relatively same number of shares.
LIQUIDITY AND CAPITAL RESOURCES
- -------------------------------
During the first nine months of 2004, our working capital increased
$4,184,000 to $107,116,000 from $102,932,000 at December 31, 2003. The increase
was principally due to cash generated by operations, cash received from employee
equity plans and a reduction in finance loans which was partially offset by
purchase of treasury stock and investment in property and equipment. Our cash
and cash equivalents and investment securities position increased during the
nine months ended September 30, 2004 by $8,442,000 to $81,579,000 from
$73,137,000 at December 31, 2003. This is because the aggregate of cash provided
by operating activities (including tax benefits from exercise of stock options)
of $18,292,000, cash provided by the company's employee equity plans of
$3,148,000 and net receipts of $2,267,000 under finance loans exceeded the
purchases of treasure stock of $10,133,000 and property and equipment of
$5,080,000.
OPERATING ACTIVITIES: Our cash provided by operating activities tends
to increase over time because of our operating results. However, it is subject
to fluctuations, principally from changes in accounts receivable, inventories,
current liabilities, investments in capital equipment and tax benefits from
exercise of stock options.
21
Normally the substantial majority of our accounts receivable are
current or no more than thirty days past due. In recent years, the majority of
each quarter's sales have been in that last half of the quarter with the result
that the amount of accounts receivable reported as of the end of each quarter
tends to be higher than the amounts at other times during a quarter.
Accounts receivable decreased from $24,943,000 at December 31, 2003
to $14,437,000 at September 30, 2004, or 42%; the decrease was principally
because revenue in the third quarter of 2004 was 45% less than revenue in the
fourth quarter of 2003.
We generally try to maintain a minimal amount of inventory of
finished goods and work in process, but will maintain larger amounts of
components (classified as raw material) acquired from third parties to avoid
production delays if deliveries by our suppliers are late. However, in order to
avoid production inefficiencies caused by fluctuating production levels, we have
begun to level out our production volumes and build finished goods of our
standard (non-custom) products to meet anticipated future orders. Because of
Hospira's decision to reduce their inventory levels we expect to reduce
production in the remainder of 2004.
Inventories increased $6,159,000 from $3,398,000 at December 31, 2003
to $9,557,000 at September 30, 2004 principally because of our decision to
increase our production volumes beyond current orders and increase our finished
goods inventories in anticipation of higher revenues for the in the latter part
of 2004. Revenue will now be less than originally anticipated. This caused our
finished good inventory to increase in the first nine months of 2004, but we
expect finished good inventories to begin to return to levels in line with
anticipated sales during the second quarter of 2005.
Our current liabilities tend to fluctuate based on the timing of when
liabilities are incurred and paid. The largest single source of fluctuation has
been income tax liabilities, and those fluctuations are generally a function of
the timing and amount of estimated tax payments in relation to actual tax
liabilities.
The tax benefits from the exercise of stock options, which we believe
is more properly related to the sale of our stock which is a financing activity,
fluctuates based principally on when employees choose to exercise their vested
stock options. Tax benefits from the exercise of stock options in the first nine
months of 2004 were $1,923,000 on the exercise of options to acquire 228,211
shares as compared to $994,000 in the first nine months of 2003 on the exercise
of options to acquire 61,939 shares.
We expect to incur a net loss in the fourth quarter of 2004. However,
we expect that a reduction in receivables and inventories and other working
capital accounts will enable us to generate positive cash flow from operations
in the fourth quarter of 2004.
INVESTING ACTIVITIES: During the first nine months of 2004 we used
cash of $6,888,000 in investing activities. This was comprised primarily of
purchases of property and equipment of $5,080,000 and the net purchases of
liquid investments of $4,075,000 utilizing cash generated by operations in
excess of other investing needs, partially offset by the net cash receipt of
$2,267,000 in finance loans.
Capital expenditures were at a relatively high rate in 2003,
principally because of our expansion in Mexico, including an electron-beam
sterilizer, and investment in molds, molding equipment, automated assembly
equipment, computers and software. Capital expenditures in the first nine months
of 2004 of $5,080,000 were principally to maintain capacity and for building
efficiency improvements. We currently estimate that capital expenditures for the
remainder 2004 will be approximately $1,000,000, bringing the year's total to
approximately $6,080,000. Amounts of spending are estimates and actual spending
may substantially differ from those amounts.
Upon completing an evaluation of the design and capacity of our
manufacturing facilities, we estimate that our current facilities will be
adequate for our business as it currently exists through 2005, but that
production after 2005 may require additional clean room facilities for molding
and automated assembly. We expect to decide in the future how to meet the need
for any additional facilities and the location of additional clean room
facilities for molding and automated assembly.
22
ICU Finance, Inc. is a wholly owned consolidated subsidiary that we
established in 2002 as a licensed commercial lender to provide financing to
companies involved in distribution of healthcare products and provision of
healthcare services. Loans are made only to credit-worthy healthcare entities
and are fully secured by real and personal property. At September 30, 2004, it
had $6,640,000 in loans outstanding. Scheduled maturities are: remainder of 2004
$312,000; 2005 $2,719,000; 2006 $1,181,000; 2007 $1,157,000 and 2008 $1,271,000.
Weighted average maturity (principal and interest) at September 30, 2004 was 1.4
years and the weighted average interest rate was 5.4%. In October 2003, we
discontinued new lending activities. We will honor existing lending commitments.
The maximum that can be borrowed under all commitments, including amounts
outstanding, was approximately $6,748,000 at September 30, 2004. This is down
from almost $13,000,000 at the end of the fourth quarter 2003 primarily due to
the expiration or reduction of lending agreements.
FINANCING ACTIVITIES: Cash provided by stock options and the employee
stock purchase plan, excluding tax benefits, was $3,148,000 in the first nine
months of 2004 as compared to $1,280,000 in the first nine months of 2003:
options were exercised on 228,211 shares in the first nine months of 2004 as
compared with 61,939 in the first nine months of 2003.
We spent $10,133,000 to acquire shares of our common stock in the
first nine months of 2004 as compared to $15,323,000 in the first nine months of
2003. We may purchase our shares in the future. However, future purchases of our
common stock, if any, will depend on market conditions and other factors.
We have a large cash and liquid investment position generated from
profitable operations and stock sales, principally from the exercise of employee
stock options. We maintain this position to fund our growth, meet increasing
working capital requirements, fund capital expenditures, and to take advantage
of acquisition opportunities that may arise. Our primary investment goal is
capital preservation, as further described in Item 3. Quantitative and
Qualitative Disclosures about Market Risk. Our liquid investments have very
little credit risk or market risk. We currently believe that our existing cash
and liquid investments along with funds expected to be generated from future
operations will provide us with sufficient funds to finance our current
operations for the next twelve months.
OFF BALANCE SHEET ARRANGEMENTS
We have agreed to indemnify officers and directors of the Company to
the maximum extent permitted under Delaware law and to indemnify customers as to
certain intellectual property matters related to sales of our products. There is
no maximum limit on the indemnification that may be required under these
agreements. We have never incurred, nor do we expect to incur, any liability for
indemnification. Except for indemnification agreements, we do not have any "off
balance sheet arrangements".
CONTRACTUAL OBLIGATIONS
We have the following contractual obligations of approximately the
following amounts. These amounts exclude purchase orders for goods and services
for current delivery; we do not have any long-term purchase commitments for such
items.
Payments due: less than 1 year
Total from September 30, 2004
----- -----------------------
Property and equipment $830,000 $830,000
======== ========
23
FORWARD LOOKING STATEMENTS
- --------------------------
Various portions of this Report, including this Management's
Discussion and Analysis, describe trends in our business and finances that we
perceive and state some of our expectations and beliefs about our future. These
statements about the future are "forward looking statements," and we identify
them by using words such as "believe," "expect," "estimate," "plan," "will,"
"continue," "could," may," and by similar expressions and statements about aims,
goals and plans. The forward looking statements are based on the best
information currently available to us and assumptions that we believe are
reasonable, but we do not intend the statements to be representations as to
future results. They include, among other things, statements about:
o future operating results and various elements of operating results,
including future expenditures on sales and marketing and product
development, sales and unit volumes of products, future license, royalty
and revenue share income, production costs, gross margins, SG&A, and R&D
expense, income, losses, cash flow, new product introductions, changes in
working capital items such as receivables and inventory, selling prices
and income taxes;
o factors affecting operating results, such as shipments to specific
customers, expansion in international markets, selling prices, the market
shift to needleless technology, future increases or decreases in sales of
certain products and in certain markets and distribution channels, impact
of safety legislation, increases in systems capabilities, introduction and
sales of new products, overhead absorption, manufacturing efficiencies,
unit manufacturing costs, acquisition and use of production equipment and
expansion of facilities and assembly capacity, expansion of markets and
the need for additional facilities, business seasonality and fluctuations
in quarterly results, customer ordering patterns and warranty claims,
rebates and returns;
o new or extended contracts with manufacturers and buying organizations, and
dependence on a small number of customers, effect of Abbott's spin-off of
its Hospital Products Division, effect of contract amendments with
Hospira, ability to replace distributors, and the outcome of our strategic
initiatives;
o regulatory approval and outcome of litigation; competitive and market
factors, including continuing development of competing products by other
manufacturers, the impact of Cardinal's acquisition of Alaris,
consolidation of the healthcare provider market and downward pressure on
selling prices; and working capital requirements, changes in accounts
receivable and inventories, current liabilities, foreign currency
denominated financial instruments, capital expenditures, acquisitions of
other businesses or product lines, indemnification liabilities,
contractual liabilities and common stock repurchases.
The kinds of statements described above and similar forward looking
statements about our future performance are subject to a number of risks and
uncertainties which one should consider in evaluating the statements. First, one
should consider the factors and risks described in the statements themselves.
Those factors are uncertain, and if one or more of them turn out differently
than we currently expect, our operating results may differ materially from our
current expectations.
Second, one should read the forward looking statements in conjunction
with the Risk Factors in our Current Report on Form 8-K to the Securities and
Exchange Commission dated February 15, 2002 which is incorporated by reference.
Third, our actual future operating results are subject to other
important factors that we cannot predict or control, including among others the
following:
o general economic and business conditions;
o the effect of price and safety considerations on the healthcare
industry;
o competitive factors, such as product innovation, new technologies,
marketing and distribution strength and price erosion;
o unanticipated market shifts and trends;
24
o the impact of legislation affecting government reimbursement of
healthcare costs;
o changes by our major customers and independent distributors in their
strategies that might affect their efforts to market our products;
o unanticipated production problems; and
o the availability of patent protection and the cost of enforcing and
of defending patent claims.
We disclaim any obligation to update the statements or to announce publicly the
result of any revision to any of the statements contained herein to reflect
future events or developments.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
- ------------------------------------------------------------------
We have a portfolio of corporate preferred stocks and
federal-tax-exempt state and municipal government debt securities. The
securities are all "investment grade" and we believe that we have virtually no
exposure to credit risk. Dividend and interest rates reset at auction for most
of the securities from between seven and forty-nine day intervals, with some
longer but none beyond twelve months, so we have very little market risk, that
is, risk that the fair value of the security will change because of changes in
market interest rates; they are readily saleable at par at auction dates, and
can normally be sold at par between auction dates. As of September 30, 2004, we
had no declines in the market rates of these securities.
Our future earnings are subject to potential increase or decrease
because of changes in short-term interest rates. Generally, each one-percentage
point change in the discount rate will cause our overall yield to change by
two-thirds to three-quarters of a percentage point, depending upon the relative
mix of federal-tax-exempt securities and corporate preferred stocks in the
portfolio and market conditions specific to the securities in which we invest.
At September 30, 2004 we had outstanding commercial loans of
approximately $6,640,000. Loans are made only to credit worthy parties and are
fully secured by real and personal property. We plan to hold the loans until
maturity or payoff. Maturities are five years or less and the weighted average
maturity (principal and interest payments) is 1.4 years. Because of the
relatively small amount of the commercial loans, market risk is not significant
to our financial statements.
Foreign currency exchange risk for financial instruments on our
balance sheet, which consist of cash, accounts receivable and accounts payable,
is not significant. Sales from the U.S. to foreign distributors are all
denominated in U.S. dollars. We have manufacturing, sales and distribution
facilities in several countries and we conduct business transactions denominated
in various foreign currencies, principally the Euro, British Pound, and Mexican
Peso. Cash and receivables in those countries have been insignificant and are
generally offset by accounts payable in the same foreign currency. We expect
that in the future, with the growth of our European distribution operation, that
net Euro denominated instruments will increase. We currently do not hedge our
foreign currency exposures.
Our exposure to commodity price changes relates primarily to certain
manufacturing operations that use resin. We manage our exposure to changes in
those prices through our procurement and supply chain management practices and
the effect of price changes have not been material. We are not dependent upon
any single source for any of our principal raw materials or products for resale,
and all such materials and products are readily available.
ITEM 4. CONTROLS AND PROCEDURES
- -------------------------------
Our principal executive officer and principal financial officer have
concluded, based on their evaluation of our disclosure controls and procedures
(as defined in Regulations 13a-14(c) and 15a-14(c) under the Securities Exchange
Act of 1934) as of the end of the period covered by this report, that our
disclosure controls and procedures are effective to ensure that the information
25
we are required to disclose in the reports that we file or submit under the
Exchange Act is accumulated and communicated to our management, including our
principal executive officer and principal financial officer, as appropriate to
allow timely decisions regarding required disclosure and that such information
is recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the Securities Exchange Commission. There
were no significant changes in our internal controls or in other factors that
could significantly affect our internal controls subsequent to the date of the
principal executive officer's and principal financial officer's evaluation,
including any corrective actions with regard to significant deficiencies and
material weaknesses.
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
- -------------------------
In an action filed August 21, 2001 entitled ICU MEDICAL, INC. V. B
BRAUN MEDICAL, INC. pending in the United States District Court for the Northern
District of California, we allege that B. Braun infringes ICU's patent by the
manufacture and sale of its UltraSite medical connector. On December 30, 2003,
we were awarded an additional patent and on December 30, 2003 we filed an
additional action against B. Braun for patent infringement and moved to amend
the 2001 action to include that allegation. The 2001 action has since been
amended to include our claim of infringement of the additional patent. We seek
monetary damages and injunctive relief and intend to vigorously pursue this
matter. The outcome of this matter cannot be determined at this time
In an action filed June 16, 2004 entitled ICU MEDICAL, INC. V. ALARIS
MEDICAL SYSTEMS, INC. pending in the United States District Court for the
Central District of California, we allege that Alaris Medical Systems, Inc.
infringes ICU's patent in the manufacture and sale of the SmartSite and
SmartSite Plus Needle-Free Valves and Systems. We seek monetary damages and
injunctive relief and intend to vigorously pursue this matter. On August 2, 2004
the Court denied our request for a preliminary injunction. The outcome of this
matter cannot be determined at this time.
We are from time to time involved in various other legal proceedings,
either as a defendant or plaintiff, most of which are routine litigation in the
normal course of business. We believe that the resolution of the legal
proceedings in which we are involved will not have a material adverse effect on
our financial position or results of operations.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
- -------------------------------------------------------------------
(a) Inapplicable
(b) Inapplicable
26
(c) ISSUER PURCHASES OF EQUITY SECURITIES
(d)
(c) Maximum
Total Number
Number (or Shares
of Shares Approximate
(or Units) Dollar Value)
(b) Purchased as Of Shares (or
(a) Total Average Part of Units) that May
Number of Price Publically Yet be
Shares (or Paid per Announced Purchased
Units) Share Plans or Under the Plans
Period Purchased (or Unit) Programs Or Programs
- --------------------------- ------------------------ ------------------------ ------------------------- ------------------------
July 2004 194,548 $27.61 0 Not applicable
- --------------------------- ------------------------ ------------------------ ------------------------- ------------------------
August 2004 171,296 $27.80 0 Not applicable
- --------------------------- ------------------------ ------------------------ ------------------------- ------------------------
Total 365,844 $27.74 0
- --------------------------- ------------------------ ------------------------ ------------------------- ------------------------
Shares were acquired in open-market transactions pursuant approval by the Board
of Directors which does not specify any limitation on the number of shares that
may be repurchased.
ITEM 3. DEFAULT UPON SENIOR SECURITIES
- --------------------------------------
Inapplicable
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
- -----------------------------------------------------------
Inapplicable
ITEM 5. OTHER INFORMATION
- -------------------------
None
ITEM 6. EXHIBITS
- ----------------
Exhibit 31.1: Certifications of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2: Certifications of Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32: Certifications of Chief Executive Officer and Chief
Financial Officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
27
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ICU Medical, Inc.
(Registrant)
/s/FRANCIS J. O'BRIEN Date: November 8, 2004
- ---------------------
Francis J. O'Brien
Chief Financial Officer
(Principal Financial Officer)
/s/SCOTT E. LAMB Date: November 8, 2004
- ---------------------
Scott E. Lamb
Controller
(Principal Accounting Officer)
28